ACC, STS Launch IDE Study of Alternative Approaches to TAVR
Note: Since the launch of Transcatheter Valve Therapies (TVT) Alternative Access for Inoperable Patients Investigational Device Exemption (IDE) study, a number of process-related questions have been raised by hospitals participating in the STS/ACC TVT Registry and other stakeholders. The TVT Registry is working closely with the Food and Drug Administration (FDA) and Edwards Lifesciences to address these questions. As a result, effective Aug. 30, the IDE study will be on hold and will not enroll new patients until further notice. Additional information will be posted on the TVT Registry website when it becomes available.
The ACC and The Society of Thoracic Surgeons (STS) investigational device exemption (IDE) study to assess alternative access approaches for transcatheter aortic valve replacement (TAVR) launched on July 16.
"The goal behind the study is to expand the field and extend the benefits of TAVR to broader patient groups," said former ACC President David Holmes, Jr., MD, MACC. "This should be a model for specialty societies, industry and federal regulators aligning efforts to ensure appropriate patient access to a new technology in a cost-effective and evidence-based way."
The ACC and STS worked closely with the FDA, the Centers for Medicare and Medicaid Services and Edwards Lifesciences to develop the trial, which will be tracked using the STS/ACC TVT Registry™. As part of the trial, patients not eligible for aortic valve surgery will receive TAVR through transapical, transaortic, and other non transfemoral approaches. These data will be compared to those of patients in the original PARTNER Cohort A trial who received TAVR through the transapical approach.
"The approval of the IDE represents the next step in the collaboration between the professional societies, CMS, the FDA and our medical device manufacturers," said former STS President Michael Mack, MD, FACC. "The process required all parties to be flexible and innovative while navigating these 'uncharted waters.' This is an iterative process that we hope will allow the safe and timely introduction of new medical device technology to our patients."
"The beauty of using the STS/ACC TVT Registry is that we can continue to gain a truly complete picture of the risks and benefits of different approaches to TAVR," said Holmes. "Having the data in one place means we can conduct further data analysis for outcome assessment, fulfill regulatory mandates, and potentially identify and implement additional new proposals and protocols to make TAVR accessible to more patients."
Moving forward, the STS and ACC are working to gain FDA approval to perform two additional studies examining the role of alternative approaches in high-risk patients who are eligible for surgery and valve-in-valve TAVR procedures, respectively. In addition, Holmes notes that collaborations with other international registries have also been initiated.
"We have learned much about TAVR since its approval a little more than a year ago," said Holmes. "The continued application of new, more advanced technology, the presentation and publication of new trial data, and more optimal matching of devices and patients moving forward will allow even greater utilization of the attributes of this transformational technology in years to come."
Keywords: Heart Valve Prosthesis, United States Food and Drug Administration, Centers for Medicare and Medicaid Services, U.S., Risk Assessment
< Back to Listings